# AbbVie Inc. (ABBV) FY2025 Q1 P&L / Income Statement

- Company: AbbVie Inc. (ABBV)
- Period: 2025-01-01 to 2025-03-31
- Filing: Q1 FY2025 10-Q, filed 2025-05-09, accession number 0001551152-25-000029
- Page: https://plicit.ai/financials/abbv/fy2025-q1-income-statement
- Chart image: https://plicit.ai/charts/abbv-fy2025-q1-income-statement-sankey.png

## Chart details: Revenue by Key Product Portfolio by Product and Service

Income statement for 2025-01-01 through 2025-03-31. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 13,343,000,000 US dollars
- **Cost of products sold**: 4,002,000,000 US dollars
- **Gross profit (calculated)**: 9,341,000,000 US dollars
- **Operating expenses (calculated)**: 5,608,000,000 US dollars
- **Operating earnings**: 3,733,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 2,072,000,000 US dollars
- **Earnings before income tax expense**: 1,661,000,000 US dollars
- **Income tax expense**: 372,000,000 US dollars
- **Net earnings**: 1,289,000,000 US dollars
- **Aesthetics - Botox Cosmetic**: 556,000,000 US dollars
- **Aesthetics - Juvederm Collection**: 231,000,000 US dollars
- **Aesthetics - Other Aesthetics**: 315,000,000 US dollars
- **Eye Care - Alphagan/Combigan**: 60,000,000 US dollars
- **Eye Care - Lumigan/Ganfort**: 106,000,000 US dollars
- **Eye Care - Other Eye Care**: 217,000,000 US dollars
- **Eye Care - Ozurdex**: 123,000,000 US dollars
- **Oncology - Elahere**: 179,000,000 US dollars
- **Oncology - Epkinly**: 51,000,000 US dollars
- **Oncology - Imbruvica**: 738,000,000 US dollars
- **Oncology - Venclexta**: 665,000,000 US dollars
- **Immunology - Humira**: 1,121,000,000 US dollars
- **Immunology - Rinvoq**: 1,718,000,000 US dollars
- **Immunology - Skyrizi**: 3,425,000,000 US dollars
- **Neuroscience - Botox Therapeutic**: 866,000,000 US dollars
- **Neuroscience - Duodopa**: 96,000,000 US dollars
- **Neuroscience - Other Neuroscience**: 59,000,000 US dollars
- **Neuroscience - Qulipta**: 193,000,000 US dollars
- **Neuroscience - Ubrelvy**: 240,000,000 US dollars
- **Neuroscience - Vraylar**: 765,000,000 US dollars
- **Neuroscience - Vyalev**: 63,000,000 US dollars
- **Other Key Products - Linzess/Constella**: 148,000,000 US dollars
- **Other Key Products - Mavyret**: 306,000,000 US dollars
- **Undisclosed (calculated)**: 1,102,000,000 US dollars
- **Acquired IPR&D and milestones**: 248,000,000 US dollars
- **Research and development**: 2,067,000,000 US dollars
- **Selling, general and administrative**: 3,293,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $1.29 B; to noncontrolling interests: $3.00 M.